Please login to the form below
Vaccibody name Martin Bonde as CEO
He joins from EpiTherapeutics where he holds the same role
Norwegian cancer vaccine company Vaccibody has appointed Dr Martin Bonde as CEO, effective from August 10.
Bonde has over 25 years of international experience in the biotech industry, starting his career at Dako and going on to work at companies including Ostemeter, Visiopharm and Aros Pharma.
He joins from EpiTherapeutics, where he has held the role of CEO since 2009.
Tom Pike, chairman of Vaccibody, said: "We are delighted to welcome Martin Bonde to Vaccibody. The Vaccibody technology has a wide business development potential within many market segments, which will benefit greatly from Martin's extensive track record in deal making.
“We also believe that our ability to attract an experienced industry executive with Martin's credentials reflect positively on Vaccibody's' considerable potential”.
Bonde's experience in the sector includes a number of transactions within business development, trade sales, mergers and acquisitions and management of research and development.
Featured jobs
-
Medical Writer
-
Salary TBC
-
Senior Account Manager
-
Competitive Salary Offered
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Account Director, Medical Education
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Account Director
-
Competitive Salary Offered
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Account Manager / Account Director
-
Competative
-
Business Director
-
Competitive Salary Offered
-
Associate Director
-
£75, 000-90, 000
- Global Business Development Director – Health Education
-
excellent commission
Subscribe to our email news alerts
- Pfizer takeover rumour ignites Amarin shares
- AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief
- BMS and Celgene deal sparks debate on pharma profit motive, more M&A
- NICE rejects Novartis migraine treatment Aimovig
- GSK upbeat on its return to oncology market
- Nektar confirms BMS deal for NKTR-214 is on track
- Digital applications are transforming the market access landscape
- Porterhouse Medical Group adds to its growing team of scientific and medical experts
- Global ban on pharma freebies, including cultural gifts
- AZ’s Sean Bohen to exit after business overhaul; report
- Lucid Group welcomes new talent into their 2019 Futures Academy
- Chinese biotechs aim PD-L1 antibody at hepatitis B
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
- Escaping the spin cycle of sub-optimal launch
- ...
- NHS Long Term Plan - Digital is firmly on the agenda. Are you ready?
- The message is clear. To keep pace with the NHS, pharma and healthcare companies must act now and refine their digital strategy to meet the needs of a transforming NHS....
Quick links
Infographics
